Scopolamine, a tertiary amine anticholinergic, plays a key role in anesthesia due to its antiemetic and sedative properties. It is primarily used to manage postoperative nausea and vomiting (PONV) and motion sickness, but its effects extend beyond these uses due to its ability to block muscarinic receptors in both the central nervous system (CNS) and peripheral tissues. Scopolamine is often used in conjunction with anesthesia to enhance patient comfort and reduce the risk of complications related to nausea, vomiting, and excessive parasympathetic activity.
Mechanism of Action
Scopolamine works by competitively inhibiting muscarinic receptors, particularly the M1 receptor. By blocking acetylcholine at these receptors, scopolamine reduces parasympathetic activity, resulting in smooth muscle relaxation, decreased glandular secretion, and central sedation. Muscarinic receptors are concentrated in the vestibular nuclei and the nucleus of the solitary tract, the medullary relays that feed the vomiting center. By blocking them, scopolamine effectively prevents nausea and vomiting, making it a useful antiemetic in both the preoperative and postoperative phases of anesthesia. Because the chemoreceptor trigger zone is driven mainly by dopamine and serotonin rather than acetylcholine, scopolamine is most effective when combined with agents from those classes rather than used alone.
Scopolamine also exerts sedative and amnestic effects, particularly when administered in higher doses. This sedation is valuable during anesthesia, as it helps manage anxiety and discomfort. However, scopolamine’s CNS effects can vary, as over-excitement and restlessness may occur at high doses, particularly in sensitive populations like the elderly.
Postoperative Nausea and Vomiting (PONV)
One of the primary FDA-approved uses of scopolamine in anesthesia is the prevention of postoperative nausea and vomiting (PONV). PONV is a common complication following general anesthesia, often resulting from opioid analgesia, the effects of anesthetic drugs, or surgical stress. Scopolamine is typically administered in transdermal patch form before surgery to prevent nausea and vomiting. The patch contains 1.5 mg of scopolamine and is programmed to deliver about 1 mg over 72 hours; the slow release provides extended protection against PONV, making it especially useful for longer surgeries or procedures known to have a high risk of postoperative nausea. In a meta-analysis of 25 randomized trials, the patch cut PONV in the first 24 hours by about a quarter (relative risk 0.77), at the cost of more visual disturbance and dry mouth, and the current consensus guideline lists it as one of the standard prophylactic options to combine with a 5-HT3 antagonist or dexamethasone in patients at moderate or high risk.
In the app: the Master Anesthesia app's PONV Risk calculator (Calculators, then PONV Risk) scores the four Apfel factors in four taps and returns the expected incidence of PONV without prophylaxis, the risk tier, and a tiered prophylaxis plan, so you can decide before the patient leaves preop whether a scopolamine patch belongs in the plan.
The patch is applied behind the ear (postauricular area) at least 4 hours before surgery or the night before to allow for adequate absorption and onset of action. For cesarean sections, it is applied 1 hour before surgery to reduce exposure to the baby while still providing the antiemetic effect. For the PONV indication the patch is removed 24 hours after surgery; if it is left on, protection continues for up to 72 hours. Scopolamine can also be given intravenously or intramuscularly (0.3 to 0.6 mg in adults) as an antisialagogue or sedative premedication, a use that has largely given way to glycopyrrolate because of scopolamine's sedation and delirium.
| Point | Detail |
|---|---|
| Dose delivered | Patch contains 1.5 mg; delivers about 1 mg of scopolamine over 72 hours |
| Application site | Behind the ear (postauricular area) |
| Timing, most surgery | At least 4 hours before surgery, or the night before, to allow absorption and onset |
| Timing, cesarean section | 1 hour before surgery — limits exposure to the baby while still giving the antiemetic effect |
| Removal | 24 hours after surgery for PONV prophylaxis; protection lasts up to 72 hours if left in place |
| After applying | Wash hands; accidental eye contact causes blurred vision and dilated pupils |
| Before MRI | Remove the patch — it contains metal and can cause burns during imaging |
| If toxicity develops | Physostigmine reverses the anticholinergic effects |
Prevention of Motion Sickness
In addition to preventing PONV, scopolamine is widely used to treat motion sickness, a condition that occurs when the brain receives conflicting signals about movement. Scopolamine’s action on the M1 receptors in the vestibular system and vomiting center makes it effective in preventing nausea and vomiting triggered by motion, such as during travel or in the postoperative setting where patient mobility may induce these symptoms.
Sedative and Amnestic Effects
Scopolamine’s sedative and amnestic properties make it useful in certain anesthesia contexts. While benzodiazepines are commonly used for preoperative sedation, scopolamine provides additional options, particularly for patients who may benefit from central nervous system suppression. In some cases, scopolamine is used as an off-label adjunct to anesthesia to control preoperative anxiety, reduce gastrointestinal spasms, or assist with other parasympathetic functions that may interfere with anesthesia management. However, caution is required due to the potential for agitation, restlessness, and confusion, particularly in elderly or psychiatrically vulnerable patients.
